sulfasalazine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 44 Diseases   34 Trials   34 Trials   2969 News 
44 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sulfasalazine / Generic mfg.
2017-004542-24`ACTRN12621000264886: Severe Psoriatic arthritis – Early intervEntion to control Disease: the SPEED trial

Ongoing
4
315
Europe
Methotrexate, Sulfasalazine, Leflunomide, Humira, N/A, Tablet, Injection, Methotrexate, Salazopyrin EN, Arava, Humira
University of Oxford, NIHR
Physical Inactivity , Poor dietary behaviour , Obesity , Overweight
 
 
ChiCTR2100043373: Clinical study of Hydroxychloroquine Sulfate and sulfasalazine in the treatment of active rheumatoid arthritis

Completed
4
200
 
HCQ(200mg/d)+MTX ;HCQ(400mg/d)+MTX ;HCQ(200mg/d)+SASP+MTX ;SASP+MTX
Renji Hospital, Shanghai Jiaotong University School of Medicine; Renji Hospital, Shanghai Jiaotong University School of Medicine, Project of Shanghai Science Committee
rheumatoid arthritis
 
 
ChiCTR-TRC-11001274: Integrated Traditional Chinese and Western medicine for ankylosing spondylitis

Completed
4
300
 
Qiangji Granule placebo, Sulfasalazine, Ibuprofen ;Qiangji Granule placebo, Sulfasalazine, Ibuprofen
School of Chinese Medicine Southern Medical University; Development and Reform Commission of Guangdong Province, the
ankylosing spondylitis
 
 
ChiCTR-TRC-13002981: Effectiveness and safety of Chinese herbal medicine in low responders in patient population of rheumatoid arthritis under MTX-based conventional therapy

Completed
4
220
 
GTT tablets, 10 mg 3 times a day after meals. Yi Shen Juan Bi (YSJB) ,1 pocket (8 g) 3 times a day after meals ;Methotrexate (MTX)10 mg/week and Sulfasalazine (SSZ),at an initial dose of 0.5 g three times a day in the first week, from the second week the dose was 1.0g twice a day
Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical Sciences; None, China Academy of Chinese Medical Sciences Project
rheumatoid arthritis
 
 
2006-006186-16: IMPROVED: Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic DiseaseA randomized clinical trial in patients with recent-onset arthritis to compare the efficacy of DMARD combination therapy including prednisone with combination therapy including adalimumab, a TNF-blocking agent

Ongoing
4
535
Europe
Methotrexate, Prednisone, Sulfasalazine, hydroxychloroquine, adalimumab, MTX, HCQ, hydroxychloroquine, Humira, hydroxychloroquine, Humira
Leiden University Medical Center, department of rheumatology
rheumatoid arthritis and undifferentiated arthritis
 
 
2006-004419-24: The Use of Sulfasalazine as an Anti-fibrotic in Acute Alcoholic Hepatitis

Ongoing
4
40
Europe
Sulfasalazine, Sulfasalazine, Sulfasalazine
Southampton University Hospitals Trust (R&D)
Acute Alcoholic Hepatitis
 
 
2007-001190-28: Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis

Ongoing
4
190
Europe
Methotrexate, Sulfasalazine, Hydroxychloroquine, Ciclosporin, Leflunomide, Sodium aurothiomalate (intramuscular gold), methylprednisolone, Prednisolone, Infliximab, Etanercept, Adalimumab, Azathioprine, Penicillamine, Methotrexate, Sulfasalazine, Hydroxychloroquine, Ciclosporin, Leflunomide, Sodium aurothiomalate (intramuscular gold), methylprednisolone, Prednisolone, Infliximab, Etanercept, Adalimumab, Azathioprine, Penicillamine,
King\'s College London
Rheumatoid Arthritis
 
 
2014-003260-20: CHAMP Trial: comparing monotherapy and polytherapy treatment strategies in newly diagnosed juvenile idiopathic arthritis.

Ongoing
4
130
Europe
Sulfasalazine, Hydroxychloroquine, Tablet, Methotrexate, sulfasalazine, Hydroxychloroquine
Leiden University Medical Centre, ZonMw
Juvenile idiopathic arthritis, Juvenile idiopathic arthritis jeugdreuma, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
TEEMS, NCT03813771: Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification

Not yet recruiting
4
106
Europe
Benepali, Etanercept, Sulfasalazine, Methotrexate, Hydroxychloroquine
University of Leeds, Samsung Bioepis Co., Ltd.
Rheumatoid Arthritis
02/23
02/23
2018-002735-26: A clinical study to test the effects of a apremilast compared to placebo for the treatment of patients with Psoriatic Arthritis with less than 2 years of duration and up to 4 joints involved, despite stable treatment with either non-steroidal anti-inflammatory drugs (ie aspirin, ibuprofen and naproxyn) and /or ≤ 1 non-biologic disease-modifying antirheumatic drugs (methotrexate OR sulfasalazine).

Not yet recruiting
4
330
Europe, RoW
Apremilast, CC-10004, Film-coated tablet, Otezla
Amgen Inc., Celgene Corporation, CELGENE CORPORATION, Amgen Inc, Celgene Corporation, Amgen Inc.
EARLY, OLIGOARTICULAR PSORIATIC ARTHRITIS, Mild form of joint inflammation affecting individuals with the skin disorder, psoriasis., Diseases [C] - Immune System Diseases [C20]
 
 
NCT03739853: Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial

Recruiting
4
315
Europe
Methotrexate, Sulfasalazine, Leflunomide, Adalimumab
University of Oxford
Psoriatic Arthritis
08/24
02/25
NCT03254589: Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis

Recruiting
4
124
RoW
Methotrexate, Sulfasalazine, Other DMARDs
Flinders University, University of South Australia, medac GmbH
Rheumatoid Arthritis, Stiffness, Aortic, Endothelial Dysfunction, Cardiovascular Risk Factor
12/23
12/24
ChiCTR2300072896: Cost-effectiveness of adalimumab "reduction strategies" in the treatment of rheumatoid arthritis: a multicenter, prospective, real-world observational study

Not yet recruiting
4
1000
 
None ;Adalimumab tapering combined with methotrexate therapy. The recommended dosage of adalimumab is as follows: Adalimumab, 40 mg/2 weeks, subcutaneous injection, reduce the dose after full dose treatment after reaching low disease activity. The dose reduction is carried out as follows: to extend the duration of administration and limiting the maximum duration of administration interval to 6 weeks (it is recommended to extend the duration of administration interval to 3, 4 or 6 weeks). The recommended dose of methotrexate is as follows: Methotrexate, taken orally, 10-30 mg once a week. ;triple therapy is applied. According to the patient's condition and willingness of patients, three traditional synthetic anti-rheumatic drug combination treatment could be applied, including but not limited to: methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, etc. Recommended usage and dosage are as follows: Methotrexate, oral, 10-30 mg each time, once a week; Leflunomide, 10-20 mg once daily; Sulfasalazine, orally, 500 mg-1,000 mg each time, 3-4 times a day; Hydroxychloroquine, orally, 0.2 g to 0.4 g, once a day.
The First Affiliated Hospital of Chengdu Medical College; The First Affiliated Hospital of Chengdu Medical College, Self-funded
rheumatoid arthritis
 
 
BIO3, NCT02714634: Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide

Recruiting
4
286
Europe
Methotrexate + targeted therapy administration, methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration
University Hospital, Strasbourg, France
Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide
03/25
03/25
2006-005104-14: A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma

Ongoing
3
20
Europe
Sulfasalazine, Gemcitabine,
Universitätsklinikum Schleswig-Holstein
Pancreatic ductal adenocarcinoma, non resectable
 
 
2020-001899-14: An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunosuppressive medication can be tapered without recurrence of symptoms

Not yet recruiting
3
270
Europe
Prednisolone p.o., Sulfasalazine, Leflunomide, Methotrexate p.o., Methotrexate s.c., Etanercept, Adalimumab, Infliximab, Abatacept s.c., Abatacept i.v., Tablet, Coated tablet, , Solution for injection, Powder for concentrate for solution for infusion, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Solution for injection in dose-dispenser cartridge, Prolonged-release tablet, Xeljanz 5/10mg Filmtabletten, Otezla Filmtabletten, Simponi 50mg Injektionslösung Vorgefüllter Injektor/Fertigspritze, Cimzia 200mg Injektionslösung in einem Fertigpen, Orencia Injektionslösung in einer Fertigspritze, Orencia 250mg Pulver, Cosentyx 150mg Injektionslösung in einer Fertigspritze, Taltz, Cimzia 200mg Injektionslösung in einer Fertigspritze, Cimzia 200mg Injektionslösung in einer Patrone für ein Dosiergerät, Orencia 125mg Injektionslösung im Fertigpen, Cosentyx 150mg Injektionslösung in einem Fertigpen, Stelara 45mg/90mg Injektionslösung, Xeljanz 11mg Retardtablette, Rinvoq 15 mg Retardtablette, Tremfya 100mg Injektionslösung, Skyrizi 75/150mg Injektionslösung
Universitätsklinikum Erlangen, Universitätsklinikum Erlangen
Psoriatic arthritis Psoriasisarthritis, Psoriatic arthritis Gelenkbeteiligung bei Schuppenflechte, Diseases [C] - Immune System Diseases [C20]
 
 
NCT06134388: Sulfasalazine in Patients With Metastatic Colorectal Cancer

Recruiting
3
50
RoW
Sulfasalazine
Tanta University
Metastatic Colorectal Cancer
09/25
09/26
NCT06060301: Topical Sulfasalazine and Oral Lichen Planus

Active, not recruiting
3
46
RoW
sulfasalazine 500 MG, colosalazine, corticosteroids, kenakort in orabase
Cairo University
Oral Lichen Planus, Topical Sulfasalazine, Corticosteroids
09/24
10/24
NCT04610476: Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Recruiting
3
270
Europe
Prednisolone, Prednisolone generic drugs, Sulfasalazine, Azulfidine, Leflunomide, Arava, Methotrexate, Lantarel, Metex, Tofacitinib, Xeljanz, Apremilast, Otezla, Etanercept, Enbrel, Erelzi, Benepali, Adalimumab, Humira, Amgevita, Imraldi, Hyrimoz, Infliximab, Remicade, Zessly, Inflectra, Certolizumab pegol, Cimzia, Golimumab, Simponi, Abatacept, Orencia, Secukinumab, Cosentyx, Ixekizumab, Taltz, Ustekinumab, Stelara
University of Erlangen-Nürnberg Medical School
Psoriatic Arthritis, Withdrawal, Reduction
10/24
10/25
NCT03414502: Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting
3
400
US
Methotrexate, Methotrexate (MTX), Abatacept, Orencia, Adalimumab, Humira, Azathioprine, Imuran, Baricitinib, Olimuant, Certolizumab, Cimzia, Etanercept, Enbrel, Golimumab, Simponi, Hydroxychloroquine, Plaquenil, Infliximab, Remicade, Leflunomide, Arava, Minocycline, Minocin, Rituximab, Rituxin, Sarilumab, Kevzara, Sulfasalazine, Azulfidine, Tofacitinib, Xeljanz
University of Nebraska
Rheumatoid Arthritis
03/27
03/28
ACTRN12621001347853p: Clinical study assessing the anti-cancer activity of sulfasalazine in patients with advanced or metastatic pancreatic ductal adenocarcinoma whose cancer has worsened following therapy with current standard of care.

Not yet recruiting
2
38
 
Australian Genomic Cancer Medicine Centre Ltd t/a Omico, Cancer Institute NSW
Pancreatic cancer
 
 
ACTRN12621001347853: Clinical study assessing the anti-cancer activity of sulfasalazine in patients with advanced or metastatic pancreatic ductal adenocarcinoma whose cancer has worsened following therapy with current standard of care.

Recruiting
2
38
 
Australian Genomic Cancer Medicine Centre Ltd t/a Omico, Cancer Institute NSW
Pancreatic cancer
 
 
SHIP, NCT03561584: Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

Recruiting
2
42
US
Sulfasalazine, Azulfidine, Placebo
Brigham and Women's Hospital
Primary Sclerosing Cholangitis
09/24
11/24
NCT05703425: The Effect of Sulfasalazine on CRH Levels in Pregnant Women

Recruiting
2
50
US
Sulfasalazine
Rutgers, The State University of New Jersey
Preterm Birth
01/26
06/26
NCT06360068: A Prospective, Single Arm, Open Label, Proof of Concept Clinical Study of Sulfasalazine in the Treatment of Active Systemic Lupus Erythematosus

Not yet recruiting
2
20
NA
Sulfasalazine Tablets
Qiong Fu
Systemic Lupus Erythematosus
05/25
05/25
NCT06557330: MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

Not yet recruiting
2
24
NA
Bendamustine, cytostasan, belrapzo, treanda, vivimusta, Rituximab, riabni, Rituxan, Ruxience, Truxima, Azulfidine
Fox Chase Cancer Center, Adaptive Biotechnologies
Lymphoma, Indolent Non-hodgkin Lymphoma
03/27
09/27
NCT03847311: Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients

Completed
2
10
US
Sulfasalazine, Active treatment, Placebos, Non-active
University of Arizona
Breast Cancer, Chronic Pain Due to Malignancy (Finding)
10/23
10/23
2004-004392-11: Human phase 1/2 clinical study of the safety and efficacy of sulfasalazine as a therapy for recurrent or progressing high grade gliomas.

Ongoing
1/2
20
Europe
Sulfasalazine, not applicable, Capsule*, Salazopyrine
Centre Hospitalier Universitaire de Liege
Recurrent or progressive high grade glioma, including gliobastoma, anaplastic astrocytoma and oligo-astrocytoma.
 
 
NCT04528056: Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension

Recruiting
1/2
80
RoW
Sulfasalazine, Ambrisentan, Sulfasalazine's placebo, Ambrisentan's placebo
RenJi Hospital
Pulmonary Arterial Hypertension
12/21
10/22
SALMA, NCT05580861: Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment

Recruiting
1/2
64
Europe
Sulfasalazine
Assistance Publique - Hôpitaux de Paris
Acute Myeloid Leukemia
11/25
12/26
GLUGLIO, NCT05664464: Glutamate Inhibitors in Glioblastoma

Recruiting
1/2
120
Europe
Gabapentin, Sulfasalazine, Memantine, Temozolomide, Radiotherapy
University of Zurich, Swiss National Science Foundation
Glioblastoma
06/26
12/26
SAS-GKRS, NCT04205357: Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma

Completed
1
24
Europe
Sulfasalazine, Stereotactic radiosurgery
Haukeland University Hospital, Norwegian Cancer Society, Northwell Health, Weill Medical College of Cornell University, University of Bergen, Helse Stavanger HF
Glioma, Glioblastoma, Recurrent Glioblastoma
10/22
10/22
NCT05445440: A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine

Completed
1
30
US
Methotrexate, Leucovorin, BMS-986371, CC-99677, Sulfasalazine
Bristol-Myers Squibb
Healthy Participants
11/22
11/22
ACTRN12623001038684: A drug-drug interaction trial between AR882, fluconazole, carbamazepine, celecoxib, and sulfasalazine in healthy particpants

Completed
1
54
 
Arthrosi Therapeutics Australia Pty, Ltd a subsidiary of Arthrosi Therapeutics, Inc, Arthrosi Therapeutics Australia Pty, Ltd a subsidiary of Arthrosi Therapeutics, Inc.
Gout
 
 
ChiCTR2400086784: Study on the effect of thunder-fire moxibustion on the clinical effect of acute radiation enteritis after pelvic tumor radiotherapy based on intestinal microecology

Not yet recruiting
1
82
 
Sulfasalazine + parisgut oral treatment; Thunder-fire moxibustion treatment was given based on the control group
Beijing Luhe hospital Affiliated to Capital Medical University; Beijing Municipal Commission of Health, Beijing Municipal Commission of Health
acute radiation enteritis after pelvic tumor radiotherapy
 
 
ChiCTR2000032228: Bioavailability study of Sulfasalazine Oral Suspension

Not yet recruiting
N/A
20
 
phase I: T-R; phase II: R-T ;phase I: T-R; phase II: R-T
Nanjing Nanhua orthopedic Hospital; Nanjing Nanhua Orthopedic Hospital, Self finance
Ulcerative colitis
 
 
NCT05749068: Evaluation of the CapScan Device to Measure the Metabolism of Sulfasalazine

Completed
N/A
10
US
CapScan intestinal sampling device
Envivo Bio Inc, National Cancer Institute (NCI)
Healthy
10/22
10/22
ChiCTR2000038277: The factor analysis of curative effect of AS and the indications analysis of Long-snake moxibustion based on content analysis method

Recruiting
N/A
40
 
Long-snake moxibustion ;Sulfasalazine Enteric-coated Tablets
Nanchang Hongdu Hospital of TCM; Nanchang Hongdu Hospital of TCM, Key Research and Development Project from Department of Science and Technology of Jiangxi Province
Ankylosing spondylitis
 
 
NCT06293378: Safety and Effectiveness of Sulfasalazine in the Treatment of Liver Fibrosis/Cirrhosis.

Recruiting
N/A
330
RoW
Sulfasalazine enteric-coated tablets
The Second Affiliated Hospital of Chongqing Medical University
Cirrhosis, Liver, Fibrosis, Liver
10/28
10/28
ChiCTR2100048756: Yunpi Yishen Tongdu for active ankylosing spondylitis: a prospective cohort study

Not yet recruiting
N/A
250
 
Meloxicam tablets, once a day, one tablet at a time. According to the patient's condition, sulfasalazine tablets and other recommended anti-rheumatic drugs for the treatment of AS/SpA can be added. ;On the basis of the non-exposure group, Yunpi Yishen Jiedu Tongdu granules were added.
Zhejiang University of Traditional Chinese Medicine; The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine, self-funded
ankylosing spondylitis
 
 
ChiCTR2300075871: Study on the maintenance strategy of biological agents for elderly rheumatoid arthritis based on treat to target

Not yet recruiting
N/A
70
 
Follow up every 12 weeks to evaluate the Treatment to Target. If not reach the target, first increase the TNFi dose to the standard dose, and then adjust the csDMARDs (including methotrexate, Tripterygium wilfordii, Iguratimod, leflunomide, hydroxychloroquine, and sulfasalazine); If reach the target, the TNFi was reduced and maintained until the maintenance dose was achieved. The order of reduction was YSP/ETA 50mg QW, 25mg QW, 25mg Q2W (maintenance dose), ADA 40mg Q2W, Q3W, Q4W (maintenance dose), and csDMARDs remained unchanged.; Follow up every 12 weeks to evaluate the Treatment to Target. If not reach the target, first increase the TNFi dose to the standard dose, and then adjust the csDMARDs (including methotrexate, Tripterygium wilfordii, Iguratimod, leflunomide, hydroxychloroquine, and sulfasalazine); If reach the target, the TNFi was reduced and maintained until the maintenance dose was achieved. The order of reduction was YSP/ETA 50mg QW, 25mg QW, 25mg Q2W (maintenance dose), ADA 40mg Q2W, Q3W, Q4W (maintenance dose), and csDMARDs remained unchanged.
Beijing Hospital; Beijing Hospital, National High Level Hospital Clinical Research Funding
rheumatoid arthritis
 
 
SurviTreat, NCT03440892: Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients

Recruiting
N/A
2500
Europe
methotrexate, sulfasalazine, Salazopyrin, abatacept, Orencia, tocilizumab, RoActemra, tofacitinib/baricitinib, Xeljanz/Olumiant
Vastra Gotaland Region
Rheumatoid Arthritis
01/25
01/25
CHOIR, NCT04725422: CHronic Nonbacterial Osteomyelitis International Registry

Recruiting
N/A
2000
US
Methotrexate, Sulfasalazine, Azulfidine, Leflunomide, areva, Pamidronate, Aredia, Zoledronic acid, Etanercept, enbrel, Adalimumab, humira, Certolizumab, cimzia, Infliximab, remicade, inflectra, Golimumab, simponi, NSAID
Seattle Children's Hospital, Boston Children's Hospital, Boston, MA, USA, Hospital for Special Surgery, New York, Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, USA, Riley Children's Hospital, Indianapolis, IN, USA, University of North Carolina, Chapel Hill, NC, USA, Royal Children's Hospital, Melbourne, Australia, Hacettepe University, Ankara, Turkey, Bambino Gesù Children's Hospital, Rome, Italy, University of British Columbia, Vancouver, BC, Canada, Meyer Children's Hospital, Florence, Italy, Mansoura University, University of Utah, Salt Lake City, UT, USA, University of Iowa Carver College of Medicine, Iowa City, IA, USA, Ann & Robert Lurie Children's Hospital of Chicago, Chicago, IL, USA, Palacky University Olomouc Institute of Molecular and Translational Medicine, Olomouc, Czechia, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, UK, University of Calgary, Calgary, Alberta, Canada
Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
08/28
08/50
ACTRN12617000226303: Treating preterm preeclampsia with sulfasalazine: An early phase clinical trial

Recruiting
N/A
20
 
Mercy Hospital for Women, Norman Beischer Medical Research Foundation
Preeclampsia
 
 

Download Options